The $4 Billion Pill That Just Embarrassed Bristol Myers
Takeda's oral psoriasis pill zasocitinib just beat BMS's Sotyktu in a head-to-head trial, delivering more than double the complete skin clearance rate. The first direct showdown between two TYK2 inhibitors could reshape the autoimmune market and put serious pressure on BMS's underperforming franchise.
Imagine spending years building the only house on a quiet street, only to watch someone move in next door with a bigger yard, better curb appeal, and a lower mortgage. That's roughly what just happened to Bristol Myers Squibb.
Takeda announced that its oral psoriasis pill, zasocitinib, beat BMS's Sotyktu (deucravacitinib) in a head-to-head Phase 3 trial. Not on some secondary measure buried in the appendix. On the primary endpoint: complete skin clearance at 16 weeks. And it won on every key secondary endpoint, too.
This is the first time two TYK2 inhibitors (a newer class of targeted pills for autoimmune diseases) have been tested directly against each other in a late-stage clinical trial. The result wasn't close.
The Scoreboard
The trial, called LATITUDE Atlas, enrolled adults with moderate-to-severe plaque psoriasis and randomized them to either zasocitinib or Sotyktu. The primary endpoint was PASI 100 at Week 16, which translates to a simple question: how many patients had their skin completely clear after four months?
On zasocitinib, 35% of patients hit complete clearance. On Sotyktu, the rate was more than 2.5 times lower. Zasocitinib also won on PASI 90 (clear or almost clear skin) and sPGA 0 (a physician's rating of fully clear skin), both at Week 16.
To put the Sotyktu number in context: when BMS ran its original psoriasis trials a few years ago, only about 14% and 10% of patients on Sotyktu achieved complete clearance at Week 16 versus placebo in POETYK PSO-1 and PSO-2, respectively. The head-to-head result lines up with that. Zasocitinib roughly doubled Sotyktu's best performance.
Safety was consistent with prior zasocitinib studies, with no new signals. The most common side effects were upper respiratory infections (about 10%), acne (about 6.5%), and nasopharyngitis (about 6.2%).
Why This Matters More Than a Decimal Point
In psoriasis, there's a hierarchy of results that doctors and patients care about. PASI 75 (a 75% improvement in skin disease) used to be the gold standard. Then the bar moved to PASI 90. Now the conversation is about PASI 100: total clearance, zero visible disease.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
For years, only injectable biologics (like Skyrizi, Tremfya, and the IL-17 drugs) could reliably get patients there. Oral pills were the consolation prize: convenient, sure, but you traded clearance for comfort. Sotyktu was the first oral TYK2 inhibitor to reach the market, and it represented a step forward from older pills like Otezla. But dermatologists still reached for injectables when they wanted the best results.
Zasocitinib's numbers change that equation. Across Takeda's broader Phase 3 program (two placebo-controlled trials plus this head-to-head), more than half of patients achieved PASI 90 by Week 16, and roughly 30% hit PASI 100. Those are biologic-like numbers in a once-daily pill. Responses showed up as early as Week 4 and kept improving through Week 24.
Think of it like this: Sotyktu proved that an oral TYK2 pill could work in psoriasis. Zasocitinib is proving that an oral TYK2 pill can work really well.
A $291 Million Problem for Bristol Myers
Sotyktu's commercial story has been, to put it gently, underwhelming. The drug brought in about $291 million globally in 2025, up about 18% from 2024. That's respectable growth, but it's a far cry from the $4 billion peak sales that some analysts once projected. BMS even had to push back its broader new-product revenue target by a year because drugs like Sotyktu and Zeposia were ramping slower than planned.
The PsA (psoriatic arthritis) approval in March 2026 was supposed to be the turning point, making Sotyktu the first TYK2 inhibitor approved in that indication. And it still has that first-mover advantage; zasocitinib isn't on the market yet.
But head-to-head data is the currency that physicians, payers, and pharmacy benefit managers trade in. Once zasocitinib gets approved (Takeda plans to file with the FDA during fiscal year 2026), every formulary negotiation for Sotyktu gets harder. Every physician conversation gets more complicated. Insurance companies now have an evidence-based reason to prefer a competitor.
The near-term impact on BMS revenue is probably minimal; Sotyktu still has the field to itself for now. But the long-term ceiling for the franchise just got lower. Analyst forecasts for Sotyktu's psoriasis peak sales are likely headed for a trim.
Takeda's $4 Billion Bet Looks Pretty Smart
Rewind to 2022. Takeda paid $4 billion upfront (with another $2 billion in milestones) to acquire zasocitinib from Nimbus Therapeutics. At the time, some people thought that was aggressive for a drug that hadn't finished Phase 2.
Four years later, Takeda has a clean Phase 3 sweep in psoriasis, a head-to-head win over the only marketed competitor, and a filing timeline that could put zasocitinib on pharmacy shelves within the next couple of years. The company has guided to $3 to $6 billion in peak sales across multiple indications, including psoriasis, psoriatic arthritis, and inflammatory bowel disease.
For context, Takeda's blockbuster gut drug Entyvio faces patent erosion later this decade. Zasocitinib is increasingly looking like the franchise that backfills that gap. Jefferies analysts have described the drug's profile as "best-in-class" for oral psoriasis, suggesting it could "redefine the oral psoriasis market."
The Three-Horse Race Nobody Expected
Zasocitinib isn't the only challenger. Alumis reported positive Phase 3 psoriasis data for its own TYK2 inhibitor, envudeucitinib, back in January 2026, with an FDA filing planned for the second half of the year. Some analysts think envudeucitinib could have an efficacy edge of its own based on early data.
So the TYK2 landscape is about to go from a monopoly to a three-way fight. BMS had psoriasis to itself; now it's facing two well-armed competitors with strong data, both racing toward 2026-2027 approvals.
And don't forget the broader context. The global psoriasis treatment market is roughly $30 billion in 2025 and growing at nearly 10% annually. Biologics still command about half of that revenue, but the oral segment is the fastest-growing piece. That's a big pie, and TYK2 inhibitors are fighting for the biggest slice.
Payers are watching closely. As more oral TYK2 options enter the market, expect rebate pressure to intensify. The days of a single oral TYK2 commanding premium pricing without direct competition are ending. For patients, though, this is unambiguously good news: more competition means better drugs, better access, and eventually better prices.
What's Still Missing
A few caveats before we crown a winner. Takeda hasn't released the exact PASI 100 response rate for the Sotyktu arm of this trial; we're working with the "statistically superior" headline and context from prior Sotyktu data. Full numerical results and detailed safety comparisons will likely come at a major dermatology conference later this year.
Long-term safety is also an open question for the entire TYK2 class. Zasocitinib's Phase 3 safety data through 24 weeks look clean, but multi-year data are still being collected. The TYK2 mechanism is specifically designed to avoid the cardiovascular and cancer risks that plagued older JAK inhibitors (a related but less selective drug class), and so far the data support that theory. But "so far" isn't "forever."
The Bottom Line
Takeda just delivered the kind of data that reshapes a market. Zasocitinib didn't just match Sotyktu; it beat it convincingly, on every measure that matters, in a direct comparison.
For BMS, this is a wake-up call. The Sotyktu franchise needs new indications and global expansion to justify its place in the portfolio, because the psoriasis story alone won't cut it anymore. For Takeda, the $4 billion gamble is paying off: zasocitinib looks like a legitimate franchise drug.
And for the millions of people living with psoriasis, the message is simple. The oral pills are getting good enough to compete with needles. That's a win worth celebrating, regardless of which company's stock goes up.
4 min read
Novo Nordisk's Top Scientist Just Said the Quiet Part Out Loud
Novo Nordisk's chief scientist publicly admitted CagriSema's weight loss results are "not competitive" with Eli Lilly's retatrutide at ADA 2026. In the obesity drug arms race, that kind of candor from the incumbent is almost unheard of, and Wall Street is already picking sides.
